
    
      This is a randomized, controlled, open-label, parallel, multicenter study. Patients are
      stratified according to 3 factors ; performance status (ECOG scale: 0, 1, 2), disease stage
      (unresectable gastric cancer or recurrent gastric cancer (received prior adjuvant
      chemotherapy or not)) and participating center. Patients are randomized to one of two
      treatment arms. Arm A: Patients receive oral TS-1 twice daily on days 1-28 followed by 14
      days rest. Treatment is repeated every 42 days for up to 4 courses. Arm B: Patients receive
      CDDP iv on day 8 and oral TS-1 twice daily on days 1-21 followed by 14 days rest. Treatment
      is repeated every 35 days for up to 5 courses. Patients are followed every 6 months for up to
      2 years from the day they participates in this study.
    
  